Czech Republic
France
Germany
Norway
Netherlands
Spain
Turkey
United KingdomUpdates
SUB-TYPE: CLASS 4 CAUTION IN USE
Class 4 Caution in use- Zestoretic 20/12.5mg tablets
Atnahs Pharma UK has informed the MHRA that the Patient Information Leaflet (PIL) packaged in certain batches of Zestoretic 20mg/12.5mg Tablets contains outdated safety information
MHRA drug alert date: 27th February 2023
MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-atnahs-pharma-uk-zestoretic-20mg-slash-12-dot-5mg-tablets-el-23-a-slash-05
Pip code | Product | Supplier | Affected Batches |
0481044 | ZESTORETIC 20/12.5MG TABLETS | Atnahs Pharma UK Ltd | SB012 |
This is a caution in use only we are not accepting stock returns.
Further Information
For more information, medical information queries, replacement PIL enquiries and stock control queries, please contact: info@pharmanovia.com
SUB-TYPE: CLASS 4 CAUTION IN USE
Class 4 Caution in use- Lemsip Max cold and flu capsules
Reckitt Benckiser Healthcare (UK) Limited has informed the MHRA that a typographical error has been identified on the end flap of the outer carton of some batches of Lemsip Max Cold & Flu Capsules.
MHRA drug alert date: 23rd February 2023
Pip code | Product | Supplier | Affected Batches |
2531101 | LEMSIP MAX COLD AND FLU CAPSULES (16) | RECKITT BENCKISER | AED954 |
2531119
| LEMSIP MAX COLD AND FLU CAPSULES (8) | RECKITT BENCKISER | AED981
|
This is a caution in use only we are not accepting stock returns.
Further Information
For medical information and stock control queries please contact: ConsumerHealth_GB@Reckitt.com and / or 03332005345.
SUB-TYPE:
AmerisourceBergen ESG Report FY22
At AmerisourceBergen and Alliance Healthcare, we are united in our purpose to create healthier futures.
When we pursue our purpose, we improve health and well-being, promote a positive social and environmental impact, and inspire our team members. Healthier futures start with the health of our people and planet, which is why we are committed to building partnerships and operations that benefit our stakeholders.
Visit AmerisourceBergen to see what we have accomplished in fiscal year 2022 (FY22).
On the website, you will also find additional information that has been complied into a series of reports for readers to view. Open the reports to see our comprehensive disclosures, an abridged summary, a quick-hit overview, or highlights related to our DEI efforts.
Stay up to date with all the Alliance Healthcare in the UK ESG news by following our Linked In page here.
SUB-TYPE: FIELD SAFETY NOTICE
STOP DISTRIBUTION-EYECEE ONE PRELOADED & EYECEE ONE CRYSTAL PRELOADED INTRAOCULAR LENSES - ALLIANCE DO NOT STOCK
The MHRA is aware of reports of increased intraocular pressure in patients recently implanted with EyeCee One preloaded and EyeCee One Crystal preloaded intraocular lenses (IOLs).
MHRA drug alert date 26 January 2023
Pip code | Product | Supplier | Affected Batches |
ALLIANCE DO NOT STOCK | EyeCee One preloaded & EyeCee One Crystal preloaded intraocular lenses (IOLs) | BAUSCH AND LOMB | ALL BATCHES |
Alliance do not stock this product and therefore we are not accepting stock returns.
Advice for patients
The advice in this notice is aimed at the healthcare teams who are responsible for providing and monitoring lenses used in cataract surgery. The MHRA is urgently investigating this issue and will be advising healthcare professionals on next steps, including the need to contact patients who may be affected, as soon as more information is available. If you are affected, your healthcare professional will contact you in due course. If you or somebody in your care had cataract surgery recently and are concerned, please contact the hospital where you had surgery for advice.
SUB-TYPE:
AmerisourceBergen Announces Intent to Change Name to Cencora
Unified corporate identity reflects the organization’s global reach, impact, and purpose
CONSHOHOCKEN, Pa. (January 24, 2023) – AmerisourceBergen (NYSE: ABC) today announced its intent to change its name to better reflect its bold vision and purpose-driven approach to creating healthier futures. AmerisourceBergen intends to become Cencora. The new name represents a unified presence that will continue to fuel the company’s ongoing growth strategy and advance its impact across healthcare.
“Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care,” said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.
The name Cencora is inspired by customers and team members around the world. In addition, a shared identity will create a more inclusive experience for employees as well as a stronger employer brand to attract talent and increase employee loyalty, retention, and performance. The name tells a compelling story, boldly differentiates the company, and was created with a future-oriented mindset. AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023.
Marie Evans, Managing Director, Alliance Healthcare in the UK said: “Since Alliance Healthcare joined AmerisourceBergen, we have been able to expand, evolve, and innovate on each other’s best-in-class expertise and capabilities across the pharmaceutical supply chain. Aligning under a new brand experience will further enable us to build new services, support healthcare advancements around the world, and deliver quality service for customers even more effectively as one, united organisation. Together, our teams are working with a collective determination to create a meaningful impact across healthcare.”
The change to Cencora is aligned with the organization’s growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.
Operating as Cencora, a unified and internationally inclusive name and brand, the company will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform of pharma and biopharma services to support pharmaceutical innovation and access.
For more information, visit: www.cencora.com/uk
SUB-TYPE: CLASS 3 RECALL
CLASS 3 RECALL- LACIDIPINE 4MG TABLETS
Dr Reddy’s Laboratories (UK) Limited is recalling two batches of Lacidipine 4 mg Film-Coated Tablets as a precautionary measure due to the presence of an unknown solvent-like odour.
MHRA drug alert date: 18th January 2023
Pip code | Product description | Supplier | Batch Numbers |
6833081 | LACIDIPINE TAB 4MG | DR REDDY'S | B2202043 B2202044 |
Further Information
For medical information enquiries please contact Dr. Reddy’s Laboratories (UK) Ltd Medical Information Department at 01748 828873, or email drreddysGB@EU.ProPharmaGroup.com.
For stock control enquiries please contact Dr. Reddy’s Laboratories (UK) Ltd Customer Services Team at 01482 389858 (or main switchboard at 01482 860228), or email customerserviceuk@drreddys.com.
Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.
SUB-TYPE:
It’s been just over a year since we made our sustainability pledge
At Alliance Healthcare, we are united in our responsibility to create healthier futures.
On 1 December 2021, we announced our pledge to become Net Carbon Zero by 2030 (scope 1 and 2). We recognise that there is still much more to do, but a lot of work has been done already across the business in this time to bring us closer to achieving our commitment.
Our ambition is to be the largest independent sustainable pharmaceutical wholesaler in the UK by 2030. Take a look at our sustainability video to see how far we have come on our journey so far…
SUB-TYPE: CLASS 2 RECALL
CLASS 2 RECALL - DIOCTYL CAPSULES 100MG (100 PACK)
Reason: “UCB Pharma Ltd is recalling the above batch of product as a precautionary measure due to the presence of a foreign capsule being found in a sealed pack. The Marketing Authorisation Holder’s investigation concluded that this was the result of a product mix up during the manufacturing process.
MHRA drug alert date 18 January 2023
MHRA drug alert link:
Pip code | Product description | Livery | Batch Numbers |
0579409 | DIOCTYL CAP 100MG (100 PACK) | UCB PHARMA LTD | 322983D |
Further Information
For more information, medical or supply enquiries, please contact UCB Pharma Ltd on (+44) 01753 777100 or 0800 279 3177 (freephone) or by email at UCBCares.UK@ucb.com.
Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.
SUB-TYPE:
Gary’s Our Man of the Month
In an age when most people want fame and fortune, Chessington Service Centre delivery driver, Gary Foreman, is a rare exception. Gary’s been serving his pharmacy customers since 1992 and that’s probably why he’s been recognised in the January edition of Training Matters magazine in a Staff in the Spotlight article.
“I’ve got customers who are pharmacists now that I met when they were seven or eight years old” reminisces Gary. “They’re the sons and daughters of the original owners who grew up and went to university and have come back and taken over!”
Gary joined Alliance Healthcare in 1992. “I’ve been here nearly 31 years and I’ve done the same route for the last 26,” he says. “I started as a porter and then applied to be a van driver. Best job I’ve ever done!”
Over the last 30 years, new technology has made the job easier. A key innovation for Gary is the Smartpod which logs his route, the products for each drop and driver performance. “When I first started, they literally wrote everything on a bit of paper. This is so much easier.”
Gary enjoys the customer contact the most. “Customers make the job easy for me. I have a good chat with them, they have a good chat with me and I like being out and about driving. I wouldn’t swap it for anything,” he says. And we’re sure his customers wouldn’t swop him either. Well done Gary.
Read the full article:
SUB-TYPE: CLASS 4 CAUTION IN USE
CLASS 4 CAUTION IN USE - BYLVAY 1200 MICROGRAMS HARD CAPSULES
Class 4 Drug Caution In Use - Bylvay 1200 Micrograms Hard Capsules
Albireo AB has informed the MHRA that there is a typographical error with the text on the side panel of the bottle label for a specific batch of Bylvay 1200 micrograms Hard Capsules.
MHRA drug alert date: 3rd January 2023
MHRA drug alert link:
Pip code | Product | Supplier | Affected Batches |
ALLIANCE DO NOT STOCK | BYLVAY 1200 MICROGRAMS HARD CAPSULES | ALBIREO AB | W067208E |
This is a caution in use only we are not accepting stock returns.
Further Information
For medical information and stock control queries please contact: medinfo@Albireopharma.com